Baidu
map

Radiology:术前脑MRI分期对IA期无症状NSCLC患者预后没有影响

2022-03-21 影像小生 MedSci原创

无症状临床 IA 期非小细胞肺癌患者行脑部 MRI 分期与未行脑部 MRI 分期的患者在无脑转移生存期、脑转移时间和总生存期方面未观察到差异。

脑是非小细胞肺癌(NSCLC)患者最常受影响的胸外器官。大约10% - 20%的患者在最初出现时发现脑转移,而且转移性疾病与不良预后密切相关。大多数分期指南建议对晚期NSCLC进行常规脑MRI检查,因为对脑转移和原发癌症的积极治疗与生存相关。尽管各种指南不鼓励对临床 IA 期无症状非小细胞肺癌 (NSCLC) 患者进行脑部 MRI 进行分期,但缺乏关于其术后生存率的证据。

国立首尔大学Hyungjin Kim等在Radiology杂志发表研究文章,探讨术前脑部MRI检查是否使早期非小细胞肺癌无症状患者获得生存获益。

回顾性纳入 2009 年 2 月至 2016 年 3 月期间接受根治性切除的T1N0M0 NSCLC患者。记录了术后监测期间患者的生存和脑转移的发展。分别使用 Cox 回归和 Fine-Gray 子分布风险模型比较接受或不接受脑 MRI 分期的患者的术后累积生存率和脑转移发生率。

该研究共纳入 628 名患者(平均年龄,64 ± 10岁 ;319 名男性),其中 53%接受了脑部 MRI 分期。

在多变量分析中,脑 MRI 未显示对无脑转移生存期(风险比 [HR],1.06;95% CI:0.69,1.63;P = .79)、脑转移时间(HR,1.60; 95% CI: 0.70, 3.94; P = .29) 和总生存期 (HR, 0.86; 95% CI, 0.54, 1.37; P = .54) 的预后益处

临床IA期非小细胞肺癌患者的累积生存曲线和累积发病率图,根据术前脑MRI分期表现进行分层。(A)无脑转移生存期(log-rank检验P .20)。(B)脑转移时间的累积发生率图(灰色检验P .11)。(C)总生存率(log-rank检验P .59)和(D) 5年总生存率(log-rank检验P .91)。

综上所述,无症状临床 IA 期非小细胞肺癌患者行脑部 MRI 分期与未行脑部 MRI 分期的患者在无脑转移生存期、脑转移时间和总生存期方面未观察到差异。

原文出处

Nam JG, Hong H, Choi SH, et al. No Prognostic Impact of Staging Brain MRI in Patients with Stage IA Non-Small Cell Lung Cancer [published online ahead of print, 2022 Mar 8]. Radiology. 2022;212101. doi:10.1148/radiol.212101

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1636435, encodeId=4dc316364350c, content=<a href='/topic/show?id=409412206d9' target=_blank style='color:#2F92EE;'>#MRI分期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12206, encryptionId=409412206d9, topicName=MRI分期)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=559522645691, createdName=zywlvao, createdTime=Mon Sep 12 19:21:05 CST 2022, time=2022-09-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2069070, encodeId=6aaa20690e00a, content=<a href='/topic/show?id=bbd816043f2' target=_blank style='color:#2F92EE;'>#SCLC患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16043, encryptionId=bbd816043f2, topicName=SCLC患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Tue May 03 11:21:05 CST 2022, time=2022-05-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1692270, encodeId=ac8f16922e0e6, content=<a href='/topic/show?id=a450530853c' target=_blank style='color:#2F92EE;'>#患者预后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53085, encryptionId=a450530853c, topicName=患者预后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8f4729287700, createdName=bnurmamat, createdTime=Tue Apr 26 06:21:05 CST 2022, time=2022-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1410926, encodeId=8cd51410926e1, content=<a href='/topic/show?id=a4ed130e7d0' target=_blank style='color:#2F92EE;'>#NSCLC患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13077, encryptionId=a4ed130e7d0, topicName=NSCLC患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=06332789533, createdName=xiongliangxl, createdTime=Mon Mar 21 14:21:05 CST 2022, time=2022-03-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1485251, encodeId=31f1148525195, content=<a href='/topic/show?id=4bbe5902ed2' target=_blank style='color:#2F92EE;'>#无症状#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59027, encryptionId=4bbe5902ed2, topicName=无症状)], attachment=null, authenticateStatus=null, createdAvatar=Bioon/avatar/20180429/70baad2aa5a046c5aa2914d262de7d37.jpg, createdBy=bd077990475, createdName=12498da4m34(暂无昵称), createdTime=Mon Mar 21 14:21:05 CST 2022, time=2022-03-21, status=1, ipAttribution=)]
    2022-09-12 zywlvao
  2. [GetPortalCommentsPageByObjectIdResponse(id=1636435, encodeId=4dc316364350c, content=<a href='/topic/show?id=409412206d9' target=_blank style='color:#2F92EE;'>#MRI分期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12206, encryptionId=409412206d9, topicName=MRI分期)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=559522645691, createdName=zywlvao, createdTime=Mon Sep 12 19:21:05 CST 2022, time=2022-09-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2069070, encodeId=6aaa20690e00a, content=<a href='/topic/show?id=bbd816043f2' target=_blank style='color:#2F92EE;'>#SCLC患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16043, encryptionId=bbd816043f2, topicName=SCLC患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Tue May 03 11:21:05 CST 2022, time=2022-05-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1692270, encodeId=ac8f16922e0e6, content=<a href='/topic/show?id=a450530853c' target=_blank style='color:#2F92EE;'>#患者预后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53085, encryptionId=a450530853c, topicName=患者预后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8f4729287700, createdName=bnurmamat, createdTime=Tue Apr 26 06:21:05 CST 2022, time=2022-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1410926, encodeId=8cd51410926e1, content=<a href='/topic/show?id=a4ed130e7d0' target=_blank style='color:#2F92EE;'>#NSCLC患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13077, encryptionId=a4ed130e7d0, topicName=NSCLC患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=06332789533, createdName=xiongliangxl, createdTime=Mon Mar 21 14:21:05 CST 2022, time=2022-03-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1485251, encodeId=31f1148525195, content=<a href='/topic/show?id=4bbe5902ed2' target=_blank style='color:#2F92EE;'>#无症状#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59027, encryptionId=4bbe5902ed2, topicName=无症状)], attachment=null, authenticateStatus=null, createdAvatar=Bioon/avatar/20180429/70baad2aa5a046c5aa2914d262de7d37.jpg, createdBy=bd077990475, createdName=12498da4m34(暂无昵称), createdTime=Mon Mar 21 14:21:05 CST 2022, time=2022-03-21, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1636435, encodeId=4dc316364350c, content=<a href='/topic/show?id=409412206d9' target=_blank style='color:#2F92EE;'>#MRI分期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12206, encryptionId=409412206d9, topicName=MRI分期)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=559522645691, createdName=zywlvao, createdTime=Mon Sep 12 19:21:05 CST 2022, time=2022-09-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2069070, encodeId=6aaa20690e00a, content=<a href='/topic/show?id=bbd816043f2' target=_blank style='color:#2F92EE;'>#SCLC患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16043, encryptionId=bbd816043f2, topicName=SCLC患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Tue May 03 11:21:05 CST 2022, time=2022-05-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1692270, encodeId=ac8f16922e0e6, content=<a href='/topic/show?id=a450530853c' target=_blank style='color:#2F92EE;'>#患者预后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53085, encryptionId=a450530853c, topicName=患者预后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8f4729287700, createdName=bnurmamat, createdTime=Tue Apr 26 06:21:05 CST 2022, time=2022-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1410926, encodeId=8cd51410926e1, content=<a href='/topic/show?id=a4ed130e7d0' target=_blank style='color:#2F92EE;'>#NSCLC患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13077, encryptionId=a4ed130e7d0, topicName=NSCLC患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=06332789533, createdName=xiongliangxl, createdTime=Mon Mar 21 14:21:05 CST 2022, time=2022-03-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1485251, encodeId=31f1148525195, content=<a href='/topic/show?id=4bbe5902ed2' target=_blank style='color:#2F92EE;'>#无症状#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59027, encryptionId=4bbe5902ed2, topicName=无症状)], attachment=null, authenticateStatus=null, createdAvatar=Bioon/avatar/20180429/70baad2aa5a046c5aa2914d262de7d37.jpg, createdBy=bd077990475, createdName=12498da4m34(暂无昵称), createdTime=Mon Mar 21 14:21:05 CST 2022, time=2022-03-21, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1636435, encodeId=4dc316364350c, content=<a href='/topic/show?id=409412206d9' target=_blank style='color:#2F92EE;'>#MRI分期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12206, encryptionId=409412206d9, topicName=MRI分期)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=559522645691, createdName=zywlvao, createdTime=Mon Sep 12 19:21:05 CST 2022, time=2022-09-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2069070, encodeId=6aaa20690e00a, content=<a href='/topic/show?id=bbd816043f2' target=_blank style='color:#2F92EE;'>#SCLC患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16043, encryptionId=bbd816043f2, topicName=SCLC患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Tue May 03 11:21:05 CST 2022, time=2022-05-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1692270, encodeId=ac8f16922e0e6, content=<a href='/topic/show?id=a450530853c' target=_blank style='color:#2F92EE;'>#患者预后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53085, encryptionId=a450530853c, topicName=患者预后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8f4729287700, createdName=bnurmamat, createdTime=Tue Apr 26 06:21:05 CST 2022, time=2022-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1410926, encodeId=8cd51410926e1, content=<a href='/topic/show?id=a4ed130e7d0' target=_blank style='color:#2F92EE;'>#NSCLC患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13077, encryptionId=a4ed130e7d0, topicName=NSCLC患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=06332789533, createdName=xiongliangxl, createdTime=Mon Mar 21 14:21:05 CST 2022, time=2022-03-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1485251, encodeId=31f1148525195, content=<a href='/topic/show?id=4bbe5902ed2' target=_blank style='color:#2F92EE;'>#无症状#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59027, encryptionId=4bbe5902ed2, topicName=无症状)], attachment=null, authenticateStatus=null, createdAvatar=Bioon/avatar/20180429/70baad2aa5a046c5aa2914d262de7d37.jpg, createdBy=bd077990475, createdName=12498da4m34(暂无昵称), createdTime=Mon Mar 21 14:21:05 CST 2022, time=2022-03-21, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1636435, encodeId=4dc316364350c, content=<a href='/topic/show?id=409412206d9' target=_blank style='color:#2F92EE;'>#MRI分期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12206, encryptionId=409412206d9, topicName=MRI分期)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=559522645691, createdName=zywlvao, createdTime=Mon Sep 12 19:21:05 CST 2022, time=2022-09-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2069070, encodeId=6aaa20690e00a, content=<a href='/topic/show?id=bbd816043f2' target=_blank style='color:#2F92EE;'>#SCLC患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16043, encryptionId=bbd816043f2, topicName=SCLC患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Tue May 03 11:21:05 CST 2022, time=2022-05-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1692270, encodeId=ac8f16922e0e6, content=<a href='/topic/show?id=a450530853c' target=_blank style='color:#2F92EE;'>#患者预后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53085, encryptionId=a450530853c, topicName=患者预后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8f4729287700, createdName=bnurmamat, createdTime=Tue Apr 26 06:21:05 CST 2022, time=2022-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1410926, encodeId=8cd51410926e1, content=<a href='/topic/show?id=a4ed130e7d0' target=_blank style='color:#2F92EE;'>#NSCLC患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13077, encryptionId=a4ed130e7d0, topicName=NSCLC患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=06332789533, createdName=xiongliangxl, createdTime=Mon Mar 21 14:21:05 CST 2022, time=2022-03-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1485251, encodeId=31f1148525195, content=<a href='/topic/show?id=4bbe5902ed2' target=_blank style='color:#2F92EE;'>#无症状#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59027, encryptionId=4bbe5902ed2, topicName=无症状)], attachment=null, authenticateStatus=null, createdAvatar=Bioon/avatar/20180429/70baad2aa5a046c5aa2914d262de7d37.jpg, createdBy=bd077990475, createdName=12498da4m34(暂无昵称), createdTime=Mon Mar 21 14:21:05 CST 2022, time=2022-03-21, status=1, ipAttribution=)]

相关资讯

Ann Otol Rhinol Laryngol:一个预测特发性突聋预后的列线图

建立一个能准确预测特发性突发感音神经性听力损失(ISSNHL)预后的列线图,以期为临床治疗提供参考。

JAHA:房颤患者抗凝治疗剂量不当与卒中严重程度和预后的关系

半数患有卒中的房颤患者接受了不适当的OAC治疗。与适当的VKA治疗相比,亚治疗性VKA与更严重的卒中严重程度和更高的死亡率相关。与适当剂量的DOAC相比,在调整后的模型中,剂量不足或过量的DOAC均与

BMJ子刊:妊娠期服用二甲双胍与子代长期不良预后的风险

妊娠期接触二甲双胍(单独或联合使用胰岛素)并没有增加子代长期不良预后的风险。

ARD: 法国系统性红斑狼疮住院患者COVID-19相关器官衰竭后的生存率:一项全国性研究

COVID-19相关器官衰竭与SLE患者迟发性预后不良有关。SLE患者应该优先考虑接种anti-SARS-CoV-2疫苗。

J INTERN MED:HIV相关肺动脉高压的治疗和预后

HIV-肺动脉高压患者主要是年轻男性。尽管功能状态较好,但短期预后与年龄和性别匹配的特发性肺动脉高压/家族性肺动脉高压患者相似。在目前的队列中,口服单一疗法仍然是首选的一线治疗。

JCEM:维生素D在COVID-19预后和治疗中的作用

涉及近200万成年人的多项观察性研究表明,维生素D缺乏/不足会增加对COVID-19和严重COVID-19的易感性,尽管存在较高的偏倚和异质性风险。

Baidu
map
Baidu
map
Baidu
map